We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Schematic Approach to Defining the Prevalence of COL VI Variants in Five Years of Next-Generation Sequencing.
- Authors
Marinella, Gemma; Astrea, Guja; Buchignani, Bianca; Cassandrini, Denise; Doccini, Stefano; Filosto, Massimiliano; Galatolo, Daniele; Gallone, Salvatore; Giannini, Fabio; Lopergolo, Diego; Maioli, Maria Antonietta; Magri, Francesca; Malandrini, Alessandro; Mandich, Paola; Mari, Francesco; Massa, Roberto; Mata, Sabrina; Melani, Federico; Moggio, Maurizio; Mongini, Tiziana E.
- Abstract
Objective: To define the prevalence of variants in collagen VI genes through a next-generation sequencing (NGS) approach in undiagnosed patients with suspected neuromuscular disease and to propose a diagnostic flowchart to assess the real pathogenicity of those variants. Methods: In the past five years, we have collected clinical and molecular information on 512 patients with neuromuscular symptoms referred to our center. To pinpoint variants in COLVI genes and corroborate their real pathogenicity, we sketched a multistep flowchart, taking into consideration the bioinformatic weight of the gene variants, their correlation with clinical manifestations and possible effects on protein stability and expression. Results: In Step I, we identified variants in COLVI-related genes in 48 patients, of which three were homozygous variants (Group 1). Then, we sorted variants according to their CADD score, clinical data and complementary studies (such as muscle and skin biopsy, study of expression of COLVI on fibroblast or muscle and muscle magnetic resonance). We finally assessed how potentially pathogenic variants (two biallelic and 12 monoallelic) destabilize COL6A1-A2-A3 subunits. Overall, 15 out of 512 patients were prioritized according to this pipeline. In seven of them, we confirmed reduced or absent immunocytochemical expression of collagen VI in cultured skin fibroblasts or in muscle tissue. Conclusions: In a real-world diagnostic scenario applied to heterogeneous neuromuscular conditions, a multistep integration of clinical and molecular data allowed the identification of about 3% of those patients harboring pathogenetic collagen VI variants.
- Subjects
NEUROMUSCULAR diseases; NUCLEOTIDE sequencing; GENETIC variation; SKIN biopsy; MAGNETIC resonance; PROTEIN expression; PROTEIN stability
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 23, p14567
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms232314567